Subscribe
Facebook Twitter Instagram Youtube

Hepatitis B Initiative of Washington DC (HBI-DC)

Email

janepan@hbi-dc.org

Phone

T: + 571-274-0021

Web

www.hbi-dc.org

Address

1725 I St NW, Suite 3000, Washington DC 20006 AA United States of America
About Hepatitis B Initiative of Washington DC (HBI-DC)

Vision:

A world free from liver disease caused by hepatitis B. 

Mission:  

To mobilize communities to prevent liver disease caused by hepatitis B among Asian Americans, Pacific Islanders, African newcomers, and other high-risk groups in the Washington, D.C. metropolitan area.

Through collaborative partnerships, HBI-DC provides culturally and linguistically appropriate hepatitis B outreach, education, screening, vaccination, linkages to care, and patient navigation services for impacted communities. In 2013, HBI-DC started screening for hepatitis C as well.

Accomplishments (2009-2014)

  • Screened more than 7000 at-risk individuals for hepatitis B
  • Provided in-person education to 11,400 individuals
  • Identified over 2200 individuals vulnerable to infection in need of vaccination
  • Begun or completed hepatitis B vaccination for 1323 at-risk individuals
  • Identified and followed up with 397 individuals who are infected with HBV and 81 with HCV, giving them a chance to prevent the long-term complications of hepatitis.
  • Organized over 196 hepatitis B education, screening, or vaccination events.

Sign up to receive updates from WHA

Name(Required)
I would like to hear about(Required)
Confirm consent(Required)

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Hepatitis and PWID/harm reduction 

 

11:35 – 11:40  

Chair: WHO – Intro and set the scene.  

 

11:40 – 11:55  

Co-chair:  EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe. 

 

11:55 – 12:00 

ID 29: Ema Pos (not yet registered) 

Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation. 

 

12:05 – 12:10  

ID 152: Brian Conway (Registered in person) 

Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.

 

12:10 – 12:15 

ID 212: Jasmine West (not yet registered) 

Title: From lived experience to lived expertise: a syndemic approach. 

 

12:15 – 12:20 

ID: 299 Mercy Nyakowa (Registered in person) 

Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya 

 

12:20 – 12:25 

ID: 133 Nalinikanta Rajkumar (Registered in person) 

Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?  

 

12:25 – 12:30 

Q&A and closing remarks   

tHIS

 

IS 

 

BEN’S

 

 

 

BIG 

 

 

TEST

effective case finding strategies

Supported by Vir Biotechnology, Inc

During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.

Session Agenda

14:40 – 14:45    

Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)

14:45 – 15:05   

Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology

15:05 – 15:10    

Final remarks and close